A study suggests a 16-protein blood test, the Sjögren’s protein score, may measure salivary gland inflammation without biopsy. The score correlated with glandular inflammation, antibodies, and extraglandular disease features.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
The largest CAR-T trial for pediatric solid tumors has opened in the US and UK, enrolling up to 60 young patients across four sites. The NexTGen study targets relapsed or refractory cancers and focuses first on safety and feasibility.
Two phase 3 trials found upadacitinib 15 mg significantly improved facial and total repigmentation versus placebo at 48 weeks in nonsegmental vitiligo. The 614-patient studies also showed continued improvement over time and a safety profile consistent with prior use.
The 2026 Tandem Meetings featured new data on CAR-T, allogeneic transplantation, and supportive care. Highlights included early efficacy signals for EB-103, KITE-753, Orca-T, and NXC-201, plus comparative cardiovascular safety data for lisocabtagene maraleucel.
Recursion reported Q4 2025 financial results with $754 million in cash providing runway into early 2028. The company achieved clinical validation of its AI platform with REC-4881 showing meaningful polyp reductions in FAP patients and received its fifth Sanofi milestone payment. Full-year revenue reached $74.7 million while net loss widened to $644.8 million.
The cell therapy manufacturing market is projected to reach $14.01 billion by 2035, with CAR-T therapies dominating at 65% market share. Recent FDA approvals for new CAR-T indications and Japanese regulatory acceleration highlight growing clinical adoption, while research advances include new anti-aging protein platforms and CRISPR-based treatments.
Real-world data from over 300 large B-cell lymphoma patients treated with axicabtagene ciloleucel show response rates and survival outcomes remarkably similar to pivotal trial results, with 86% overall response rate and 74% one-year survival.
Researchers are developing personalized treatment approaches for rare and pediatric cancers using genetic profiling, AI-driven dosing, and 3D-printed medications to improve outcomes while reducing long-term toxicity.
Grail's NHS-Galleri trial of 142,000 participants failed to achieve statistically significant reduction in late-stage cancer diagnoses, though secondary endpoints showed four-fold improvement in overall cancer detection rate. Stock fell 48% following the announcement.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07587840 |
CD19/CD22 CAR-T as First-line Consolidation in Follicular Lymphoma |
RECRUITING | PHASE2 |
| NCT07583810 |
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07583771 |
A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07572175 |
Sotagliflozin as Prevention of Anthracycline-Related Cardiotoxicity |
NOT_YET_RECRUITING | PHASE2 |
| NCT07566377 |
Cord Blood Transplantation in Children and Young Adults With Blood Cancer |
RECRUITING | PHASE2 |
| NCT07553572 |
Remote Monitoring and Symptom Management Digital Application |
RECRUITING | NA |
| NCT07524530 |
Stem Cell Transplantation for Participants With Germline RUNX1 Associated Blood Cancers |
NOT_YET_RECRUITING | PHASE2 |
| NCT07513129 |
Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma |
NOT_YET_RECRUITING | PHASE1 |
| NCT07502872 |
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma |
NOT_YET_RECRUITING | PHASE2 |
| NCT07499128 |
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event |
NOT_YET_RECRUITING | NA |
